World News: 13:30 GMT Thursday 30th May 2019. [Hologic, Inc. via Businesswire via SPi World News]
Hologic, Inc. (Nasdaq: HOLX) announced today that it has signed an agreement withto distribute Hologic’s Horizon® DXA system for body composition measurement.
With over 20 years of experience, DEXA+ works with healthcare practices nationwide to implement and optimize DXA technology to grow integrative medicine, health and wellness programs. The partnership allows Hologic to expand its expertise in body composition assessment and the reach of its market-leading DXA system.
“This is a great partnership as we share a vision for, and commitment to, DXA for comprehensive body composition assessment,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “The combination of our industry-leading Horizon DXA system with the deep expertise and reach of the DEXA+ channel will expand patient access to this game-changing technology that can complement wellness and training programs.”
Already considered the gold standard in bone densitometry technology, DXA is increasingly being used for body composition assessment by both collegiate and professional athletic programs, as well as training centers across the country. The BodyLogic™ scan offered on Hologic’s Horizon DXA system provides precise and in-depth measurements including percent body fat, total lean mass, and limb comparison to detect muscle imbalances.
Financial terms of the agreement were not disclosed.
For more information about Hologic’s Horizon DXA system and BodyLogic scan, please visit.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit.
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic, BodyLogic, Horizon and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
SOURCE: Hologic, Inc.
Business Wire: 13:30 GMT Thursday 30th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.